Quest acquires Enterix for $43m:
This article was originally published in Clinica
Executive Summary
Quest Diagnostics has completed the acquisition of Enterix, the provider of its colorectal cancer screening product, the InSure Fecal Immunochemical Test. It paid $43m in cash to acquire the privately-held company, which has operations in Sydney, Australia, and Falmouth, Maine. Quest has sold InSure FIT exclusively in the US since May 2003.